iShares Nasdaq BioTech ETF

IBB-Q

NASDAQ:IBB

136.49
0.34 (0.25%)

Analysis and Opinions about IBB-Q

Signal
Opinion
Expert
TOP PICK
TOP PICK
February 2, 2018

He believes in the biotech sector. It is a concept play considering aging population. ETF that allows you to participate in many companies that would require a lot of analysis.

Show full opinionHide full opinion

He believes in the biotech sector. It is a concept play considering aging population. ETF that allows you to participate in many companies that would require a lot of analysis.

COMMENT
COMMENT
January 19, 2018

A very, very large ETF. You can take a look at the different ones. There is a great website ETF.COM where you could look at this, and it will show you some of its competitors. He thinks this is a good sector to be in.

Show full opinionHide full opinion

A very, very large ETF. You can take a look at the different ones. There is a great website ETF.COM where you could look at this, and it will show you some of its competitors. He thinks this is a good sector to be in.

COMMENT
COMMENT
December 7, 2017

Sold Amgen (AMGN-Q) and bought this. Good move? He likes biotechs, but you need to recognize that it is a higher beta space and will be more volatile than other areas or other industries. There are some names in this he likes, but there are a couple that are not doing so well. He would rather pick and choose individual names, but that is going to create more risk because you are going to concentrate on 1 or 2 names. With IBB you get a more diversified risk. Thinks the space is going to do fine.

Show full opinionHide full opinion

Sold Amgen (AMGN-Q) and bought this. Good move? He likes biotechs, but you need to recognize that it is a higher beta space and will be more volatile than other areas or other industries. There are some names in this he likes, but there are a couple that are not doing so well. He would rather pick and choose individual names, but that is going to create more risk because you are going to concentrate on 1 or 2 names. With IBB you get a more diversified risk. Thinks the space is going to do fine.

TOP PICK
TOP PICK
November 17, 2017

When looking at sector rotation, biotech technology to a certain degree, is sort of in the middle. The strong rotation we’ve seen has been in industrials, energy and financials, but healthcare is sort of in the middle. This is at a good level to step in. Not for the faint of heart.

Show full opinionHide full opinion

When looking at sector rotation, biotech technology to a certain degree, is sort of in the middle. The strong rotation we’ve seen has been in industrials, energy and financials, but healthcare is sort of in the middle. This is at a good level to step in. Not for the faint of heart.

TOP PICK
TOP PICK
September 21, 2017

This is a long-term theme. We are going to have a little bit of resistance at his initial target of $3.90. (Chart actually shows around $380. Did he misspeak? - Bill) There is some volatility with some pretty big swings.

Show full opinionHide full opinion

This is a long-term theme. We are going to have a little bit of resistance at his initial target of $3.90. (Chart actually shows around $380. Did he misspeak? - Bill) There is some volatility with some pretty big swings.

COMMENT
COMMENT
August 30, 2017

He is very positive on the biotech sector. There had been a lot of negative news cycle during the election, so the sector consolidated for some time. He then got back in through this ETF in March. He just sold this, but only because of a portfolio rebalancing. A great way to play Biotech’s.

Show full opinionHide full opinion

He is very positive on the biotech sector. There had been a lot of negative news cycle during the election, so the sector consolidated for some time. He then got back in through this ETF in March. He just sold this, but only because of a portfolio rebalancing. A great way to play Biotech’s.

PAST TOP PICK
PAST TOP PICK
August 18, 2017

(Top Pick Jun 28/17, Down 4.04%) Season strength is June to September for Biotech. It is the ramp up ahead of cold and flu season. It broke a significance line and we are re-testing it. Momentum has come out of the name in the last three weeks. There is the continuous overhang of high drug prices in the US. If it cannot hold $300 then get out of it. It is no longer supported as a seasonal trade and he would get out of it.

Show full opinionHide full opinion

(Top Pick Jun 28/17, Down 4.04%) Season strength is June to September for Biotech. It is the ramp up ahead of cold and flu season. It broke a significance line and we are re-testing it. Momentum has come out of the name in the last three weeks. There is the continuous overhang of high drug prices in the US. If it cannot hold $300 then get out of it. It is no longer supported as a seasonal trade and he would get out of it.

TOP PICK
TOP PICK
June 28, 2017

The period of seasonal strength for biotech stocks is basically from mid-June to mid-September. The average gain for the NASDAQ Biotech technology index is about 8.17%, and has been positive 70% of the time since 1993. In this past week, it has broken out above the substantial trading range between $240 and $300. With the breakout, we can expect the magnitude of the range of about $60, to propel it to the upside by about $60, so the upside target is about $360.

Show full opinionHide full opinion

The period of seasonal strength for biotech stocks is basically from mid-June to mid-September. The average gain for the NASDAQ Biotech technology index is about 8.17%, and has been positive 70% of the time since 1993. In this past week, it has broken out above the substantial trading range between $240 and $300. With the breakout, we can expect the magnitude of the range of about $60, to propel it to the upside by about $60, so the upside target is about $360.

COMMENT
COMMENT
May 30, 2017

A good time to Short? The one biotech ETF that he is really familiar with is this one. Most of the Short story is already built-in, so he would be reluctant to Short. Some of the names in this are doing okay, but some are at all-time lows. He would be reluctant to Short this.

Show full opinionHide full opinion

A good time to Short? The one biotech ETF that he is really familiar with is this one. Most of the Short story is already built-in, so he would be reluctant to Short. Some of the names in this are doing okay, but some are at all-time lows. He would be reluctant to Short this.

COMMENT
COMMENT
May 18, 2017

Got into this couple of years ago, and it just never seemed to stop. Then it “stopped”. Now it seems to be stuck in a range and it is pretty close to the top of the range at almost $300. He loves the concept. There are going to be more demand for the products, and it is a real money maker.

Show full opinionHide full opinion

Got into this couple of years ago, and it just never seemed to stop. Then it “stopped”. Now it seems to be stuck in a range and it is pretty close to the top of the range at almost $300. He loves the concept. There are going to be more demand for the products, and it is a real money maker.

TOP PICK
TOP PICK
May 11, 2017

All biotech shares are pretty volatile, and there have been some pretty big moves in the last couple of months. He expects this to run up and hit the high of $380, and then run past that. This is a generational change. Good space to be in long-term. 10 years and you should be very happy.

Show full opinionHide full opinion

All biotech shares are pretty volatile, and there have been some pretty big moves in the last couple of months. He expects this to run up and hit the high of $380, and then run past that. This is a generational change. Good space to be in long-term. 10 years and you should be very happy.

COMMENT
COMMENT
December 28, 2016

This space, along with healthcare in general, is in a secular long-term move, bullish in January and February with strong seasonality on a 5-year basis. It has been beaten up politically starting with Clinton, and we are not sure if that carries through with Trump. This is not for the faint of heart, but if you have a longer-term perspective, there is support at around $260, and if you get above about $300, there is probably going to be a bit of a break out. If you are looking to trade this, you would probably take a position right now. For a longer-term perspective, you may want to initiate a position now and see what happens with the new administration.

Show full opinionHide full opinion

This space, along with healthcare in general, is in a secular long-term move, bullish in January and February with strong seasonality on a 5-year basis. It has been beaten up politically starting with Clinton, and we are not sure if that carries through with Trump. This is not for the faint of heart, but if you have a longer-term perspective, there is support at around $260, and if you get above about $300, there is probably going to be a bit of a break out. If you are looking to trade this, you would probably take a position right now. For a longer-term perspective, you may want to initiate a position now and see what happens with the new administration.

WATCH
WATCH
November 7, 2016

Biotech ETF. Institutions use this to trade. At Friday’s close we got closer to the 52 week lows. Hillary came out with a tweet about coming after the biotechs. He likes this long term for growth. He would be cautious here. No more than a third of a position. It could go 10 or 15% lower if she wins.

Show full opinionHide full opinion

Biotech ETF. Institutions use this to trade. At Friday’s close we got closer to the 52 week lows. Hillary came out with a tweet about coming after the biotechs. He likes this long term for growth. He would be cautious here. No more than a third of a position. It could go 10 or 15% lower if she wins.

PAST TOP PICK
PAST TOP PICK
October 7, 2016

(A Top Pick Sept 4/15. Down 15.71%.) Clinton indicated she was going to do something about drug prices in the US, and this got whacked. In the last quarter or so, it is up 10%-20%, so it is working its way back.

Show full opinionHide full opinion

(A Top Pick Sept 4/15. Down 15.71%.) Clinton indicated she was going to do something about drug prices in the US, and this got whacked. In the last quarter or so, it is up 10%-20%, so it is working its way back.

COMMENT
COMMENT
October 6, 2016

He sees absolutely nothing wrong with being in the biotech sector. The fees are going to be low.

Show full opinionHide full opinion

He sees absolutely nothing wrong with being in the biotech sector. The fees are going to be low.

Showing 16 to 30 of 66 entries